CardioVascular Center Frankfurt, Frankfurt, Germany.
Catheter Cardiovasc Interv. 2013 Apr;81(5):825-36. doi: 10.1002/ccd.24329. Epub 2012 Aug 20.
We sought to examine acute and midterm results of closure of multiple interatrial communications with staged device deployment and to review the relevant literature.
Information about percutaneous methods of closure for multiple defects is limited.
We treated 148 patients with multiple defects. Of these, 88 had a relevant left to right shunt ("LRS"), 52 had a presumed paradoxical embolism ("PPE"), five had both (LRS and PPE), and one patient, respectively, had migraine, decompression sickness, and a right to left shunt. After implantation of the first device, closure of additional septal defects was attempted only if indicated clinically.
Ninety-four patients received a single device and 53 more than one. In four patients, surgical defect closure followed. At the end of follow-up (FU; mean 4.5 ± 3.4 years), complete closure of all defects occurred in 67.6% (62.1% for LRS, 76.5% for PPE). Clinical success (small or trivial residual shunt) was achieved in 86.9% (83.9% for LRS, 90.2% for PPE). Complications included pericardial effusions in 2.7%, recurrent thromboembolic events in 4.8%, and new onset of atrial fibrillation in 10.1%. In a significant number of patients with multiple defects, after single device implantation, the likelihood of complete closure increased with FU time (26% complete closure at 1 month vs. 78% at 24 months).
Percutaneous closure of multiple interatrial communications is feasible and safe. Importantly, many residual defects close without further intervention at FU. Therefore, staged device delivery is an alternative to simultaneous device implantation, possibly requiring fewer and smaller second devices.
我们旨在研究分期装置部署下,闭合多个房间隔缺损的急性和中期结果,并回顾相关文献。
关于经皮闭合多个缺陷的方法信息有限。
我们治疗了 148 例患有多个缺陷的患者。其中 88 例有相关的左向右分流(“LRS”),52 例有推测的反常栓塞(“PPE”),5 例同时存在 LRS 和 PPE,1 例分别患有偏头痛、减压病和右向左分流。植入第一个装置后,如果临床上有指征,仅尝试闭合其他间隔缺损。
94 例患者接受了单个装置,53 例患者接受了多个装置。有 4 例患者随后接受了手术缺陷闭合。在随访结束时(平均 4.5±3.4 年),所有缺陷的完全闭合率为 67.6%(LRS 为 62.1%,PPE 为 76.5%)。获得了 86.9%的临床成功率(小或轻微残余分流)(LRS 为 83.9%,PPE 为 90.2%)。并发症包括心包积液 2.7%,复发性血栓栓塞事件 4.8%,新发心房颤动 10.1%。在许多患有多个缺陷的患者中,在单个装置植入后,随着随访时间的延长,完全闭合的可能性增加(1 个月时完全闭合率为 26%,24 个月时为 78%)。
经皮闭合多个房间隔缺损是可行且安全的。重要的是,许多残余缺陷在随访期间无需进一步干预即可闭合。因此,分期装置输送是同时装置植入的替代方案,可能需要更少和更小的第二个装置。